ArticleJournal of virus eradication2021
Unwillingness of patients in Ghana to interrupt antiretroviral therapy for HIV cure research.
Article in Journal of virus eradication, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 17 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
17 citing papers in PubMed, 1 synthesis or guideline pooled it.
- The Importance of Social Engagement in the Development of an HIV Cure: A Systematic Review of Stakeholder Perspectives.AIDS and behavior · 2023Pooled it
- Perceptions of young people living with HIV and caregivers in Botswana on analytical treatment interruption studies: a qualitative approach.HIV research & clinical practice · 2026Article
- HIV dominates T-cell immune responses in HIV-HBV co-infection and is associated with increased HIV reservoir transcription.Scientific reports · 2026Article
- Towards inclusive HIV cure development: Identifying important and acceptable HIV cure attributes and strategies among people with HIV in the Netherlands.HIV medicine · 2026Article
- 'It is scary to pause treatment': perspectives on HIV cure-related research and analytical treatment interruptions from women diagnosed during acute HIV in Durban, South Africa.HIV research & clinical practice · 2025Article
- Integrating socio-behavioral, ethics, community, and translational science considerations in HIV cure research.Current opinion in HIV and AIDS · 2025Review
- Understanding of HIV cure research in a rural community with high prevalence: the case of uMkhanyakude district, KwaZulu-Natal, South Africa.AIDS research and therapy · 2025Article
- High prevalence of co-infections with latent tuberculosis, syphilis and hepatitis B and C among people with HIV in Ghana: a call for integrating screening into routine care.AIDS research and therapy · 2025Article
- The impact of COVID-19 on HIV care: a comprehensive analysis of patient and healthcare providers experiences at the largest HIV treatment center in Ghana.BMC health services research · 2025Article
- Antiretroviral pause for HIV remission trials: A mixed methods study of people living with HIV in Soweto, South Africa.PLOS global public health · 2025Article
- Factors affecting viral suppression or rebound in people living with HIV and receiving antiretroviral therapy in Ghana.Frontiers in public health · 2025Article
- Relatively high interest but limited active engagement in HIV cure research: Awareness, interest, and information-seeking among affected communities in the Netherlands.Journal of virus eradication · 2024Article
- 'With this study, we have hope that something is coming': community members' perceptions of HIV cure-related research in Durban, South Africa - a qualitative focus group study.HIV research & clinical practice · 2023Article
- Temporal trend analysis of the HIV/AIDS burden before and after the implementation of antiretroviral therapy at the population level from 1990 to 2020 in Ghana.BMC public health · 2023Article
- Healthcare Provider Perspectives on HIV Cure Research in Ghana.AIDS research and treatment · 2023Article
- Article
- Underrepresentation of Africa in HIV cure research: A systematic review of the literature from 2010 to 2022.Clinical epidemiology and global healthArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesThough antiretroviral therapy (ART) has reduced HIV infection into a manageable chronic disease, it does not provide for a cure. HIV cure trials may carry risks for patients who are generally doing well on ART, making it imperative that their input is sought as various types of cure methods and trials are designed. Few studies have sought the views of African patients on HIV cure studies. The objective of this study was to determine the views and preferences of people living with HIV (PLWH) in Ghana on cure research.
methodsWe used a questionnaire to interview 251 PLWH in Ghana about their willingness to engage in HIV cure research. We investigated their motivations, the types of cure they would prefer and which risks were acceptable to them.
resultsMost participants were enthusiastic about participating in cure research and driven by both altruistic and personal motives. Patients preferred a cure where they would continue follow-up with their doctor (88%) compared to being assured that they have been completely cured and did not need further follow-up (11%). The vast majority of the respondents were risk averse. Most patients (67%) would decline to interrupt ART as part of a protocol for HIV cure research. In bivariate analysis, participants above the age of 40 years were more likely to agree to treatment interruption during cure studies (OR 2.77; 95% CI 1.21-.6.34.
conclusionsOur results show that preferred cure modalities and risk tolerance for patients in Africa may be different from those of other parts of the world. Extensive social science and behavioural studies are needed on the continent to help inform future cure trials.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.